ATAI - ATAI: Enormous Potential Upside But No Clarity Yet

2024-05-27 09:06:18 ET

Summary

• Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged.
• Major news items, such as FDA approval for MDMA-Assisted therapy and phase III data for COMP-360, are expected to impact the psychedelic drug industry.
• ATAI, an investment platform, offers cost control, diversification, and strategic investments, making it an attractive choice over COMPASS Pathways.

I first wrote about Atai Life Sciences ( ATAI ) in October 2022, rating it a buy, at the time, I thought the psychedelic drug discovery industry offered enormous potential to revolutionize care for people with a wide variety of mental health issues.

In a series of articles on the Psychedelic drug space, I also wrote about COMPASS Pathways ( CMPS ), Cybin ( CYBN ) and MindMed ( MNMD ). CMPS appeared to be the front-runner and I rated it a strong buy as it moved toward a phase III trial of its proprietary drug COMP-360....

For further details see: